Gamma-2 Herpesviruses as Vaccine Vectors for AIDS
$530,253R37FY2016AINIH
University Of Miami School Of Medicine, Coral Gables FL
Investigators
Linked publications & trials
Paper 33910957Paper 33657166Paper 33028714Paper 32193241Paper 31568531Paper 31118261Paper 30642966Paper 30541854Paper 29912986Paper 29875239Paper 29432452Paper 28732035Paper 28660888Paper 28592531Paper 28503929Paper 26504241Paper 24899181Paper 23696734Paper 21900170Paper 21613403Paper 20172576Paper 17451774
Abstract
DESCRIPTION (provided by applicant): Results of both monkey and human trials have highlighted the difficulties in achieving vaccine protection against SIV and HIV. Persistent, recombinant herpes viruses are being used in monkeys to try to match the degree of protection that can be achieved with live attenuated strains of SIV. Results to date have been promising but the absence of anti-Env antibody responses from the recombinant herpes viruses has been a glaring deficiency. The proposed experiments will overcome this deficiency and allow full testing of the promise of this approach.
View original record on NIH RePORTER →